You are currently on the new version of our website. Access the old version .
MDPIMDPI

3 Results Found

  • Article
  • Open Access
43 Citations
5,704 Views
12 Pages
Download PDF

(−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer

  • Joan Crous-Masó,
  • Sònia Palomeras,
  • Joana Relat,
  • Cristina Camó,
  • Úrsula Martínez-Garza,
  • Marta Planas,
  • Lidia Feliu and
  • Teresa Puig
Molecules2018, 23(5), 1160;https://doi.org/10.3390/molecules23051160

11 May 2018

(−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas. To improve the...

Full Article
  • Article
  • Open Access
18 Citations
4,070 Views
12 Pages
Download PDF

Mulberry Leaf Polyphenol Extract and Rutin Induces Autophagy Regulated by p53 in Human Hepatoma HepG2 Cells

  • Meng-Hsun Yu,
  • Ming-Chang Tsai,
  • Chi-Chih Wang,
  • Sheng-Wen Wu,
  • Ya-Ju Chang,
  • Cheng-Hsun Wu and
  • Chau-Jong Wang
Pharmaceuticals2021, 14(12), 1310;https://doi.org/10.3390/ph14121310

15 December 2021

The edible leaves of the mulberry (Morus alba L.) plant are used worldwide. They contain abundant polyphenolic compounds with strong anticancer properties. We previously revealed that apoptosis was mediated in p53-negative Hep3B cells, and mulberry l...

Full Article
  • Article
  • Open Access
19 Citations
3,995 Views
18 Pages
Download PDF

Fatty Acid Synthase Inhibitor G28 Shows Anticancer Activity in EGFR Tyrosine Kinase Inhibitor Resistant Lung Adenocarcinoma Models

  • Emma Polonio-Alcalá,
  • Sònia Palomeras,
  • Daniel Torres-Oteros,
  • Joana Relat,
  • Marta Planas,
  • Lidia Feliu,
  • Joaquim Ciurana,
  • Santiago Ruiz-Martínez and
  • Teresa Puig
Cancers2020, 12(5), 1283;https://doi.org/10.3390/cancers12051283

19 May 2020

Epidermal growth factor receptor (EGFR) tyrosine kinases inhibitors (TKIs) are effective therapies for non-small cell lung cancer (NSCLC) patients whose tumors harbor an EGFR activating mutation. However, this treatment is not curative due to primary...

Full Article